GSK remains an investor in the new $600m Fund II, but with a smaller financial presence as SR One positions itself to connect startups to multiple companies across the pharmaceuticals sector.

Miles Gerson, formerly senior investment director at Takeda Ventures, has been promoted to executive investment director.

Yamaha Motor's sophomore Exploratory Fund brings the amount it has committed to corporate VC to $300m in the past five years.

Seed-stage investor High-Tech Gründerfonds secured backing from a range of German corporates for its fourth fund, taking its total capital under management past €1.3bn.

Managing partner Vijay Patel tells us why CVS Health Ventures has launched a growth fund as its parent makes a big primary care play.

CVC veteran Eric Steager has left Touchdown Ventures and joined Purdue University subsidiary Purdue Ventures as managing director.

GV helped head up a 35-strong investor network backing Curie, which has raised $520m to bring CVC-like strategic help to its seed-stage drug developer portfolio.

Boston-based startup General Prognostics is developing a digital biomarker platform for heart disease patients. It is one of a growing number of emerging blood-related tech startup raising funding.

Sanofi's strategic investment arm received a top up from its pharmceutical parent in a week when it led an $80m round for its latest portfolio company.

What's going to happen to healthcare startup funding this year? Will the IPO market recover? And what kinds of technologies are on the up? We asked some leading CVCs for their view.